A trend towards lower antigen-specific CD4+ T cell levels in participants treated with JAK inhibitors was also seen when we measured the influenza-specific (Agriflu) CD4+ T cell levels at the 2–6 week post dose 3 timepoint (Fig. 3e). The gene discussed is CD4; the disease is influenza.